How to Read a Dosing Section Without Assuming More Than the Data Supports

Most of what gets repeated as a "standard dose" in this space didn't come from a clinical trial — it came from someone's forum post, repeated enough times that it started sounding official. Some real trial dosing does exist. Knowing which is which is the actual skill.

The Dose You're Reading Might Not Be For You

A dosing figure on a compound's page can mean several different things, and mixing them up is the single most common misread:

An approved, regulator-set dose. [PT-141](/compound/pt-141-10mg)'s FDA-approved dose — 1.75mg subcutaneous, as-needed, roughly 45 minutes before anticipated use — is a real number for a specific approved use. This is the strongest tier: reviewed, defined, and tied to an actual product label.

A clinical trial dose, in a different context than how it's actually used. [Ipamorelin](/compound/ipamorelin)'s real human dosing data comes from an IV dose-escalation trial — five ascending doses from 0.003 to 0.1mg/kg, with maximum GH response reached at 0.06mg/kg. That's a genuine finding. It's also an IV dose, in a supervised trial, for a compound most people actually inject subcutaneously — a different route with different absorption, so treating the IV number as a subcutaneous protocol isn't something the trial actually supports.

A dose that exists, but for a different form of the compound. [CJC-1295](/compound/cjc-1295) is a good example of why "the compound" isn't always one thing: the with-DAC form has real human trial dosing (30–90μg/kg single ascending doses, best tolerated at 30–60μg/kg). The without-DAC form has no equivalent human trial — its community-use conventions (smaller, more frequent doses) are widely discussed but untested.

No established human dose at all. [BPC-157](/compound/bpc-157)'s page is direct about this: no human clinical dose exists for self-administration. What's documented is animal dosing (context, not a protocol) and doses used in a handful of supervised human pilots — neither of which is the same thing as a validated self-administration dose. [TB-500](/compound/tb-500) is even more direct: there is no dose, animal or human, for the actual TB-500 fragment as it's commonly sold.

Community Convention Isn't the Same Confidence Level as a Trial

[Semax](/compound/semax-10mg) illustrates this well. The compound's one real clinical dosing data point is from a stroke-rehabilitation trial: 6,000mcg/day, in two 10-day courses. The dosing pattern actually discussed in most community use — 250–1,000mcg intranasally, 1–3 times a day — is a completely different, much smaller pattern that was never what was clinically tested. Both numbers exist. They answer different questions.

Why Frequency Isn't Arbitrary

Where real dosing data does exist, the frequency behind it usually isn't a stylistic choice — it tracks the compound's half-life and how it's modified. CJC-1295's DAC modification is specifically what extends its effective duration enough to support the trial's weekly-to-biweekly dosing, versus the more frequent smaller-dose pattern typically discussed for the unmodified (without-DAC) form. When a page distinguishes "with-DAC" and "without-DAC" dosing, that's the reason.

What to Actually Do With This

Before applying a number from a compound's page, check what it's actually a dose *of*: the exact form and route you have, a related form, an animal study, or an untested community pattern. Trial dosing that exists is generally there for tolerability or a specific clinical endpoint — not necessarily the same goal you have — so treating it as a target rather than a data point is its own kind of misread. Every dosage section on this site tries to keep that origin visible rather than flattening it into one confident-sounding number.